Enveda Biosciences has raised $311.0M in Series E funding, with a long list of investors backing the drug discovery company's bet that nature's chemistry can be mined faster than the industry's standard playbook.
The round drew Catalio Capital Management, Premji Invest, Iconiq, Dimension, Lightspeed Venture Partners, Durable Capital Partners, True Ventures, T. Rowe Price, Baillie Gifford, LifeForce Capital, Digitalis Ventures, Lux Capital Management, and Kinnevik. Enveda says its platform reads and translates natural chemistry at speed and scale, putting 99.9% of the natural world into the hands of drug hunters and discovering medicines four times faster than the industry average.
